For decades, China has had the largest population in the world. However, recent demographic trends have resulted in India being the world’s most populous country. COVID-19, an aging population and low birth rate have all contributed to the decrease in China’s population growth, but what does this really mean to the pharmaceutical industry?
Watch this webcast, in which our in-house experts, Marc Yates and Peggy Yau, explain the impact of the demographic shift, and the new policies that have been introduced. They provide an in-depth understanding of the pharma landscape in China which offers exciting potential, such as the breakthrough of biosimilars, the vaccination boom and Healthy China 2030 policy. The presenters further showcase where to play and how to win, providing examples spanning from market access to clinical trial design and patient journey research.
What are the key takeaways?
- Learn about the implications of the changing demographics on the healthcare landscape
- Discover Research Partnership’s take on ‘where to play, how to win’ in China
- Understand how to maximize your market research across key stakeholder groups in China